# Cancer Type Indication Profiles

Detailed biological, clinical, and commercial profiles for major oncology indications. Reference this file when analyzing specific cancer types.

## Melanoma

### Biological Profile
- **Immune landscape:** Hot, highly inflamed
- **TMB:** Very high (median ~15 mut/Mb, range 1-100+)
- **Immune archetypes:** C2 (IFN-γ, 45%), C3 (inflammatory, 30%), C1 (20%)
- **Cell states:** 
  - Progenitor exhausted CD8+: 35-40%
  - Early dysfunction: 25-30%
  - Terminal exhaustion: 15-20%
  - Effector: 10-15%
- **Spatial:** Good intratumoral T cell infiltration
- **Unique:** High neoantigen load, strong IFN signature baseline

### Pathway Analysis
- IL-2Rβ/γ expression: High on CD8+ T cells
- JAK-STAT pathway: Active
- SOCS expression: Moderate
- TGF-β: Low-moderate

### Clinical Precedent
- Anti-PD-1 monotherapy ORR: ~40% (pembro, nivo)
- Anti-CTLA-4 ORR: ~15% (ipi)
- Combination (ipi+nivo) ORR: ~58%, CR 22%
- HD IL-2 historical: ORR 16%, 6% durable CR (>10 years)
- Approved lines: 1L, 2L+

### Market Data
- US incidence: ~100,000/year total, ~7,000 metastatic
- 5-year survival (metastatic): 35% (improved with IO)
- Median age: 65
- Performance status: Generally good (outdoor/sun exposure population)

### Unmet Need
- 40-50% don't respond to checkpoint therapy
- Brain metastases (40-50% of patients) challenging
- Post-IO progression limited options
- Unmet need score: Medium-High

### Competition
- Extremely competitive: 4 approved checkpoint inhibitors
- Approved combos: ipi+nivo, pembro+epi (LAG-3)
- Active trials: >800
- Competition intensity: Very High

### Development Strategy
- **Positioning:** 2L post-IO failure, or 1L combination to boost CR rate
- **Biomarker:** CD8+ infiltration, TCF7+ progenitor abundance, TMB
- **Trial design:** Ph1b/2, biomarker-selected, N=40-60
- **Primary endpoint:** ORR (acceptable for accelerated approval)
- **Combination:** With PD-1 blockade (ipi+nivo bar is 58% ORR)

---

## Renal Cell Carcinoma (Clear Cell)

### Biological Profile
- **Immune landscape:** Constitutively inflamed (VHL → HIF → VEGF/cytokines)
- **TMB:** Moderate (median ~5 mut/Mb)
- **Immune archetypes:** C2 (50%), C3 (30%), C1 (15%)
- **Cell states:**
  - Progenitor exhausted: 30%
  - Early dysfunction: 35%
  - Effector: 20%
  - Terminal exhaustion: 15%
- **Spatial:** Highly vascularized, good immune access
- **Unique:** Chronic IFN signaling, baseline activated

### Pathway Analysis
- IL-2Rβ/γ: High expression
- JAK-STAT: Active baseline
- SOCS: Moderate (chronic signaling → feedback)
- TGF-β: Low-moderate

### Clinical Precedent
- Anti-PD-1 monotherapy: ORR ~25% (nivo)
- Nivo+ipi: ORR 42%, CR 9%
- IO+TKI combos: ORR 50-60% (pembro+axi, nivo+cabo)
- **HD IL-2:** FDA approved 1992, ORR 14-15%, 5-7% durable CR
- Approved lines: 1L (multiple), 2L+

### Market Data
- US incidence: ~76,000/year, 30% metastatic at diagnosis
- Growing incidence (obesity, hypertension links)
- Median age: 64
- Performance status: Good initially, declines with progression

### Unmet Need
- Post-IO/TKI progression: Limited options
- Non-clear cell histologies: Poor checkpoint response
- Intolerance to IO+TKI (toxicity)
- Unmet need score: Medium

### Competition
- Moderately competitive but established IO precedent
- 1L: IO+TKI combos dominating (pembro+axi, nivo+cabo)
- 2L: Less crowded (cabo, len+eve)
- Active trials: ~350

### Development Strategy
- **Positioning:** 2L post-IO, focus on durable CR rate improvement
- **Rationale:** Best historical cytokine indication, IL-2 precedent
- **Biomarker:** Angiogenic signature, immune infiltration
- **Trial design:** Ph2, post-IO population, N=80-100
- **Endpoint:** ORR/CR rate, durability
- **Advantage:** Can reference HD IL-2 durable responses as precedent

---

## Non-Small Cell Lung Cancer

### Biological Profile
- **Immune landscape:** Highly heterogeneous
  - ~30% Hot (PD-L1 ≥50%, TLS+)
  - ~30% Excluded (stromal barriers)
  - ~40% Cold
- **TMB:** Variable (median ~8 mut/Mb, wider range than most)
- **Immune archetypes:** All represented
  - Smoking: More C2/C3
  - Non-smoking: More C4/C5
- **Cell states:** Depends on subset
  - Inflamed: Good progenitor/early dysfunction
  - Cold: Terminal exhaustion or absent
- **Spatial:** Barrier by stromal desmoplasia in subset

### Pathway Analysis
- IL-2Rβ/γ: Moderate-high (in inflamed subset)
- JAK-STAT: Variable
- SOCS: Higher in smoking-associated
- TGF-β: High in excluded phenotype

### Clinical Precedent
- Anti-PD-1 monotherapy: ORR ~20% (unselected), ~45% (PD-L1 ≥50%)
- Chemo+IO: ORR 40-48%
- IO+IO: Limited benefit over monotherapy
- Approved: 1L (pembro, atezo+chemo), 2L (nivo, pembro, atezo)

### Market Data
- US incidence: ~235,000/year (largest indication)
- ~57% metastatic at diagnosis
- Median age: 70 (elderly population)
- PS: Variable, ~40% PS 2 at metastatic diagnosis

### Unmet Need
- PD-L1 negative (40%): Lower response rates
- Post-IO progression: Most patients eventually progress
- Elderly/PS 2: Tolerability challenges
- Unmet need score: High

### Competition
- **Extremely competitive:** >1200 active trials
- Multiple approved IO regimens
- IO+chemo SOC for many
- Competition intensity: Highest of any indication

### Development Strategy
- **Positioning:** Biomarker-selected subset (inflamed, PD-L1+, non-responders)
- **Challenge:** Hyper-competitive, elderly patients (toxicity concern)
- **Biomarker:** PD-L1, TMB, TLS, immune archetype
- **Trial design:** Ph1b/2, enriched population, N=60-80
- **Warning:** Must have clear differentiation vs existing IO
- **Consider:** 2L post-IO in inflamed subset only

---

## Triple-Negative Breast Cancer

### Biological Profile
- **Immune landscape:** Bimodal
  - ~20-30% Immune-enriched (TIL-high)
  - ~70-80% Immune-desert or excluded
- **TMB:** Moderate (higher than ER+ breast, lower than melanoma)
- **Immune archetypes:** 
  - Inflamed subset: C2, C3
  - Cold subset: C4, C5
- **Cell states:** (In inflamed subset)
  - Progenitor: 25%
  - Early dysfunction: 30%
  - Terminal: 25%
  - Effector: 20%
- **Unique:** TILs correlate strongly with prognosis and IO response

### Pathway Analysis
- IL-2Rβ/γ: High in TIL+ subset
- JAK-STAT: Active in inflamed
- TGF-β: High in excluded phenotype

### Clinical Precedent
- Pembrolizumab + chemo: ORR ~53% (PD-L1 CPS ≥10)
- Checkpoint monotherapy: ORR ~10-20%
- Approved: 1L pembro+chemo (PD-L1+)

### Market Data
- US incidence: ~40,000 TNBC/year
- ~20-25% of all breast cancers
- Median age: 62 (younger than other breast subtypes)
- Aggressive biology, higher relapse risk

### Unmet Need
- PD-L1 negative majority: No IO benefit
- Post-chemo+IO progression: Few options
- Metastatic relapse: Poor outcomes
- Unmet need score: High

### Competition
- Moderate competition
- 1L: Pembro+chemo establishing
- 2L+: Less developed
- Active trials: ~250

### Development Strategy
- **Positioning:** TIL-high / immune-enriched subset
- **Biomarker:** Stromal TILs, PD-L1, immune gene signatures
- **Trial design:** Ph2, biomarker-selected, N=50-70
- **Challenge:** Requires robust biomarker (not all PD-L1+ respond)
- **Opportunity:** Inflamed subset clear, unmet need post-chemo+IO

---

## Microsatellite Instability-High (MSI-H) Tumors

### Biological Profile
- **Immune landscape:** Universally hot
- **TMB:** Very high (median >40 mut/Mb, up to >100)
- **Immune archetypes:** Predominantly C2, C3
- **Cell states:**
  - Progenitor: 40%
  - Early dysfunction: 30%
  - Effector: 20%
  - Terminal: 10%
- **Neoantigen load:** Extremely high (frameshift mutations)
- **Tumor types:** CRC (4%), endometrial (30%), gastric (15%), others

### Pathway Analysis
- IL-2Rβ/γ: High
- JAK-STAT: Active
- All pathways intact (strong immune response)

### Clinical Precedent
- Anti-PD-1: ORR 40-60% across tumor types
- **Tissue-agnostic approval:** Pembrolizumab (2017)
- Durability: ~90% of responses ongoing at 2 years

### Market Data
- Prevalence: ~4% CRC, ~30% endometrial, ~15% gastric
- Small but pan-cancer opportunity
- Well-defined biomarker (PCR or IHC)

### Unmet Need
- 40-50% still don't respond to checkpoint
- Why some highly mutated tumors resist unclear
- Unmet need score: Medium (for non-responders)

### Competition
- Established: Pembrolizumab approved
- Moderate activity in space
- Active trials: ~100-150 (MSI-specific)

### Development Strategy
- **Positioning:** Combination to convert non-responders
- **Advantage:** Tissue-agnostic precedent, predictable biology
- **Challenge:** Already high response rates (bar is 40-60%)
- **Biomarker:** MSI status (diagnostic) + CD8 infiltration
- **Trial design:** Ph2, MSI-H non-responders to IO, N=40-60
- **Endpoint:** ORR in checkpoint-refractory

---

## Hepatocellular Carcinoma

### Biological Profile
- **Immune landscape:** Immunosuppressive (cirrhosis, chronic inflammation)
- **Etiology-dependent:**
  - Viral (HBV/HCV): More inflamed
  - NASH/alcohol: More fibrotic, suppressive
- **Immune archetypes:** C1 (wound healing), C6 (TGF-β), some C3
- **Cell states:** High Tregs, MDSCs, exhausted effectors
- **Unique:** Chronic tolerance from liver's immune privilege

### Pathway Analysis
- IL-2Rβ/γ: Moderate
- JAK-STAT: Variable, often suppressed
- TGF-β: High (fibrosis, suppression)
- Tolerability: Concern in cirrhotic patients

### Clinical Precedent
- Atezolizumab + bevacizumab: ORR 27%, OS 19.2mo
- Checkpoint monotherapy: ORR ~15-20%
- Approved: 1L (atezo+bev), 2L (nivo, pembro)

### Market Data
- US incidence: ~42,000/year (growing - NASH epidemic)
- Global burden much higher (Asia, Africa)
- Median age: 63
- Often Child-Pugh A required for trials (excludes sicker)

### Unmet Need
- Post-atezo+bev: Limited options
- Non-viral etiology: Worse outcomes
- Unmet need score: High

### Competition
- Moderate competition
- 1L: Atezo+bev establishing
- Active trials: ~180

### Development Strategy
- **Positioning:** Combination with TGF-β antagonist or anti-angiogenic
- **Challenge:** Immunosuppressive TME, cirrhosis tolerability
- **Biomarker:** Etiology (viral vs NASH), immune exclusion score
- **Trial design:** Ph1b/2, Child-Pugh A only, N=60-80
- **Risk:** Hepatotoxicity, cirrhotic decompensation
- **Opportunity:** High unmet need, combination rationale clear

---

## Glioblastoma

### Biological Profile
- **Immune landscape:** Cold, immunologically privileged (CNS)
- **Immune archetypes:** C4 (lymphocyte depleted), C5 (quiet)
- **Cell infiltration:** Minimal intratumoral, mostly perivascular
- **Barriers:** BBB, VEGF-driven exclusion, high Tregs/MDSCs
- **Unique:** CNS immune privilege, checkpoint failure

### Pathway Analysis
- Limited systemic T cell access
- Pathway integrity less relevant (delivery problem)

### Clinical Precedent
- Checkpoint therapy: No benefit (Checkmate 143, 548 negative)
- Vaccines: Modest/no benefit
- Historical cytokines: No significant activity

### Market Data
- US incidence: ~13,000/year
- Median survival: ~15 months (grim)
- Median age: 64

### Unmet Need
- **Extremely high:** Few advances in 20 years
- TMZ + radiation still SOC
- Unmet need score: Highest

### Competition
- Many failures, moderate ongoing activity
- Active trials: ~200 (many early-phase)

### Development Strategy
- **Warning:** Only consider if local delivery feasible
- **Approach:** Intratumoral, convection-enhanced delivery (CED)
- **Rationale:** Systemic cytokine unlikely to penetrate BBB effectively
- **Risk:** Very high technical and clinical failure risk
- **Opportunity:** Breakthrough would be major, but probability low
- **Recommendation:** Deprioritize unless novel delivery technology

---

## Pancreatic Adenocarcinoma (MSS)

### Biological Profile
- **Immune landscape:** Cold, desmoplastic stroma
- **Immune archetypes:** C4, C5, C6 (TGF-β)
- **Cell infiltration:** <5% T cells intratumoral, mostly stromal
- **Barriers:** Dense fibrosis, CAFs, physical exclusion
- **Unique:** Fundamentally non-immunogenic (low TMB)

### Pathway Analysis
- Few target cells to signal
- High TGF-β, immunosuppressive cytokines

### Clinical Precedent
- Checkpoint monotherapy: ORR ~3% (essentially no benefit)
- Chemo + checkpoint: No improvement
- Exception: MSI-H pancreatic (~1%) responds to IO

### Market Data
- US incidence: ~64,000/year
- 5-year survival: ~12% (very poor)
- Median age: 70

### Unmet Need
- **Extremely high:** Desperately needed therapies
- Chemotherapy still only option
- Unmet need score: Highest

### Competition
- Many attempts, many failures
- Active trials: ~190

### Development Strategy
- **Warning:** Cytokine monotherapy highly unlikely to work
- **Rationale:** Fundamentally cold, must prime immune system first
- **Approach:** Only as combination with:
  - Vaccine (neoantigen or shared antigen)
  - Oncolytic virus
  - Radiation (abscopal priming)
  - FAP-targeted stroma modification
- **Risk:** Extremely high failure risk
- **Recommendation:** Deprioritize unless part of comprehensive priming strategy

---

## Head and Neck Squamous Cell Carcinoma

### Biological Profile
- **Immune landscape:** Moderately inflamed, subset hot
- **HPV status impact:**
  - HPV+: More inflamed, better outcomes
  - HPV-: Less inflamed, worse outcomes
- **Immune archetypes:** Mix of C2, C3, C6
- **TMB:** Moderate-high (smoking-associated)
- **Unique:** High PD-L1 expression (~50%)

### Pathway Analysis
- IL-2Rβ/γ: Moderate-high
- JAK-STAT: Active in HPV+
- TGF-β: Higher in HPV-

### Clinical Precedent
- Anti-PD-1 (R/M): ORR ~15-18% (pembro, nivo)
- 1L pembro: ORR ~20%, approved if PD-L1 CPS ≥1
- Chemo + IO: Modest benefit

### Market Data
- US incidence: ~54,000/year
- HPV+ increasing (now ~70% of oropharynx)
- Median age: 62

### Unmet Need
- Majority don't respond to checkpoint
- Recurrent/metastatic: Poor outcomes
- Quality of life considerations (speech, swallow)
- Unmet need score: High

### Competition
- Moderate competition
- Active trials: ~280

### Development Strategy
- **Positioning:** HPV+ subset (better biology), R/M setting
- **Biomarker:** HPV status, PD-L1, immune infiltration
- **Trial design:** Ph2, HPV+ enriched, N=50-70
- **Combination:** With radiation (abscopal), or PD-1
- **Challenge:** Quality of life endpoints important
- **Opportunity:** HPV+ subset has favorable biology
